Calculating the dose of subcutaneous immunoglobulin for primary immunodeficiency disease
in patients switched from intravenous to subcutaneous immunoglobulin without the use of a dose-adjustment coefficient.
History of trauma (24%) and immunodeficiency disease
(12%) were the next most prevalent causes.
(5) Other primary immunodeficiency diseases
(PIDs) that cause recurrent mycobacterial infections include X-linked hyper-IgM syndrome, severe combined immunodeficiency syndrome and deficiencies of the IL-12/23-IFN-[gamma] axis.
(1.) Primary immunodeficiency diseases
. Report of a WHO scientific group WHO.
GeoVax HIV/AIDS vaccines are designed to prevent development of Acquired Immunodeficiency Disease
(AIDS), caused by the virus known as HIV-1, by vaccinating individuals prior to infection with the AIDS virus.
The Jeffrey Modell Foundation (JMF) is an organization dedicated to research, physician education, patient support, and public awareness of Primary Immunodeficiency Disease
Talecris produces therapies for chronic rare diseases such as alpha-1 antitrypsin deficiency (alpha-1), primary humoral immunodeficiency disease
(PI), and hemophilia.
29, 2005, during testing of a stool sample from a 7-month-old infant with severe combined immunodeficiency disease
. Subsequent testing of other community members uncovered infections from the same viral strain in three unvaccinated siblings from an unrelated family, and a fifth unvaccinated child from a third family.
A variety of other sexually transmitted infections can occur, including genital herpes, gonorrhoea, hepatitis B, syphilis and HIV (human immunodeficiency disease
A study published in the April 28, 2000, issue of "Science" describes research by French doctors who gave two infants a normal copy of a defective gene that is the leading cause of severe combined immunodeficiency disease
Enzon has two products on the market, ONCASPAR, which is used to treat Acute Lymphoblastic Leukemia (ALL), and ADAGEN a treatment for a form of Severe Combined Immunodeficiency Disease
(SCID), commonly known as the "Bubble Boy Disease".
The recent arrival on the market of a modified glucocerebrosidase (Ceredase) for Gaucher's Disease and last year's approval of PEG-adenosine deaminase for severe combined immunodeficiency disease
illustrate the growing capabilities of the pharmaceutical industry to provide endogenous compounds that patients are lacking.